New combo therapy aims to reignite immune attack on drug-resistant tumors
Disease control
Ongoing
This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC